Effects of baroreflex activation therapy on cardiac function and morphology.
Baroreflex activation therapy
Echocardiography
Electrocardiogram
HFpEF
Resistant hypertension
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
revised:
17
04
2024
received:
16
11
2023
accepted:
18
06
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
Arterial hypertension (aHTN) plays a fundamental role in the pathogenesis and prognosis of heart failure with preserved ejection fraction (HFpEF). The risk of heart failure increases with therapy-resistant arterial hypertension (trHTN), defined as inadequate blood pressure (BP) control ≥140/90 mmHg despite taking ≥3 antihypertensive medications including a diuretic. This study investigates the effects of the BP lowering baroreflex activation therapy (BAT) on cardiac function and morphology in patients with trHTN with and without HFpEF. Sixty-four consecutive patients who had been diagnosed with trHTN and received BAT implantation between 2012 and 2016 were prospectively observed. Office BP, electrocardiographic and echocardiographic data were collected before and after BAT implantation. Mean patients' age was 59.1 years, 46.9% were male, and mean body mass index (BMI) was 33.2 kg/m BAT reduced systolic and diastolic BP and was associated with morphological and functional improvement of HFpEF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317‐327. doi:10.1016/j.jacc.2003.07.046
Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: A hospital cohort study. Heart 2005;91:907‐913. doi:10.1136/hrt.2004.041996
McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, et al. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial. Eur J Heart Fail 2008;10:149‐156. doi:10.1016/j.ejheart.2007.12.010
Tadic M, Cuspidi C, Frydas A, Grassi G. The role of arterial hypertension in development heart failure with preserved ejection fraction: Just a risk factor or something more? Heart Fail Rev 2018;23:631‐639. doi:10.1007/s10741‐018‐9698‐8
Tsioufis C, Georgiopoulos G, Oikonomou D, Thomopoulos C, Katsiki N, Kasiakogias A, et al. Hypertension and heart failure with preserved ejection fraction: Connecting the dots. Curr Vasc Pharmacol 2017;16:15‐22. doi:10.2174/1570161115666170414120532
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE‐HF registry. J Am Coll Cardiol 2007;50:768‐777. doi:10.1016/j.jacc.2007.04.064
Holmqvist L, Bostrom KB, Kahan T, Schioler L, Hasselstrom J, Hjerpe P, et al. Prevalence of treatment‐resistant hypertension and important associated factors‐results from the Swedish primary care cardiovascular database. J Am Soc Hypertens 2016;10:838‐846. doi:10.1016/j.jash.2016.08.008
Mefford MT, Goyal P, Howard G, Durant RW, Dunlap NE, Safford MM, et al. The association of hypertension, hypertension duration, and control with incident heart failure in black and white adults. J Clin Hypertens (Greenwich) 2020;22:857‐866. doi:10.1111/jch.13856
Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: A report from the NHLBI‐sponsored WISE study. J Am Heart Assoc 2014;3:e000660. doi:10.1161/JAHA.113.000660
Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, et al. Prevalence, predictors, and outcomes in treatment‐resistant hypertension in patients with coronary disease. Am J Med 2014;127:71‐81.e1. doi:10.1016/j.amjmed.2013.07.038
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 2018;71:1269‐1324. doi:10.1161/HYP.0000000000000066
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021‐3104. doi:10.1093/eurheartj/ehy339
Gronda E, Dusi V, D'Elia E, Iacoviello M, Benvenuto E, Vanoli E. Sympathetic activation in heart failure(). Eur Heart J Suppl 2022;24:E4‐E11. doi:10.1093/eurheartjsupp/suac030
Grassi G, Seravalle G, Quarti‐Trevano F, Dell'Oro R, Arenare F, Spaziani D, et al. Sympathetic and baroreflex cardiovascular control in hypertension‐related left ventricular dysfunction. Hypertension 2009;53:205‐209. doi:10.1161/HYPERTENSIONAHA.108.121467
de Souza SB, Rocha JA, Cuoco MA, Guerra GM, Ferreira‐Filho JC, Borile S, et al. High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients. Am J Hypertens 2013;26:912‐917. doi:10.1093/ajh/hpt032
Piccirillo G, Germano G, Vitarelli A, Ragazzo M, di Carlo S, de Laurentis T, et al. Autonomic cardiovascular control and diastolic dysfunction in hypertensive subjects. Int J Cardiol 2006;110:160‐166. doi:10.1016/j.ijcard.2005.06.041
Floras JS. Sympathetic activation in human heart failure: Diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003;177:391‐398. doi:10.1046/j.1365‐201X.2003.01087.x
Floras JS. Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model. J Am Coll Cardiol 2009;54:375‐385. doi:10.1016/j.jacc.2009.03.061
Gronda E, Lovett EG, Tarascio M, Georgakopoulos D, Grassi G, Vanoli E. The baroreceptor as a therapeutic target for heart failure. J Cardiovasc Transl Res 2014;7:301‐309. doi:10.1007/s12265‐014‐9546‐8
Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257‐1263. doi:10.1016/0735‐1097(95)00332‐0
Kougias P, Weakley SM, Yao Q, Lin PH, Chen C. Arterial baroreceptors in the management of systemic hypertension. Med Sci Monit 2010;16:RA1–8.
Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double‐blind, randomized, placebo‐controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765‐773. doi:10.1016/j.jacc.2011.06.008
Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: Results of a European multi‐center feasibility study. J Am Coll Cardiol 2010;56:1254‐1258. doi:10.1016/j.jacc.2010.03.089
Wallbach M, Lehnig LY, Schroer C, Luders S, Bohning E, Muller GA, et al. Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension. Hypertension 2016;67:701‐709. doi:10.1161/HYPERTENSIONAHA.115.06717
Wallbach M, Lehnig LY, Schroer C, Helms HJ, Luders S, Patschan D, et al. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Hypertens 2015;33:181‐186. doi:10.1097/HJH.0000000000000361
Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015;3:487‐496. doi:10.1016/j.jchf.2015.02.006
Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 2020;76:1‐13. doi:10.1016/j.jacc.2020.05.015
Dusi V, Angelini F, Zile MR, De Ferrari GM. Neuromodulation devices for heart failure(). Eur Heart J Suppl 2022;24:E12‐E27. doi:10.1093/eurheartjsupp/suac036
Brandt MC, Madershahian N, Velden R, Hoppe UC. Baroreflex activation as a novel therapeutic strategy for diastolic heart failure. Clin Res Cardiol 2011;100:249‐251. doi:10.1007/s00392‐010‐0249‐0
Segers P, Vermeersch SJ, Wachter R, Georgakopoulos D. Effect of carotid baroreceptor activation on ventricular function and central arterial hemodynamics: A case report based on invasive pressure‐volume loop analysis. Artery Res 2011;5:166. doi:10.1016/j.artres.2011.10.068
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens 2013;31:1925‐1938. doi:10.1097/HJH.0b013e328364ca4c
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129‐2200. doi:10.1093/eurheartj/ehw128
Beige J, Jentzsch T, Wendt R, Hennig G, Koziolek M, Wallbach M. Blood pressure after blinded, randomized withdrawal, and resumption of baroreceptor‐activating therapy. J Hypertens 2017;35:1496‐1501. doi:10.1097/HJH.0000000000001339
Wallbach M, Born E, Kampfer D, Luders S, Muller GA, Wachter R, et al. Long‐term effects of baroreflex activation therapy: 2‐year follow‐up data of the BAT neo system. Clin Res Cardiol 2020;109:513‐522. doi:10.1007/s00392‐019‐01536‐5
Wallbach M, Lehnig LY, Schroer C, Hasenfuss G, Muller GA, Wachter R, et al. Impact of baroreflex activation therapy on renal function–A pilot study. Am J Nephrol 2014;40:371‐380. doi:10.1159/000368723
Infeld M, Wahlberg K, Cicero J, Plante TB, Meagher S, Novelli A, et al. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial. JAMA Cardiol 2023;8:213‐221. doi:10.1001/jamacardio.2022.5320
Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007;147:311‐319. doi:10.7326/0003‐4819‐147‐5‐200709040‐00006
Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, et al. Chronic baroreceptor activation enhances survival in dogs with pacing‐induced heart failure. Hypertension 2007;50:904‐910. doi:10.1161/HYPERTENSIONAHA.107.095216
Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 2011;4:65‐70. doi:10.1161/CIRCHEARTFAILURE.110.955013